HC Wainwright Reiterates Buy Rating for Iterum Therapeutics (NASDAQ:ITRM)

Iterum Therapeutics (NASDAQ:ITRMGet Free Report)‘s stock had its “buy” rating reissued by HC Wainwright in a research report issued on Monday, Benzinga reports. They presently have a $6.00 price target on the stock. HC Wainwright’s price target would indicate a potential upside of 275.00% from the company’s previous close.

Iterum Therapeutics Price Performance

NASDAQ ITRM opened at $1.60 on Monday. Iterum Therapeutics has a 12 month low of $0.62 and a 12 month high of $2.50. The company has a debt-to-equity ratio of 3.63, a current ratio of 2.35 and a quick ratio of 2.35. The firm has a market capitalization of $21.50 million, a PE ratio of -0.54 and a beta of 2.36. The company’s 50 day simple moving average is $1.52 and its 200 day simple moving average is $1.39.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Dimensional Fund Advisors LP acquired a new position in shares of Iterum Therapeutics during the third quarter valued at approximately $101,000. Goldman Sachs Group Inc. acquired a new position in Iterum Therapeutics in the second quarter worth approximately $61,000. Finally, Renaissance Technologies LLC grew its position in Iterum Therapeutics by 199.1% in the second quarter. Renaissance Technologies LLC now owns 323,300 shares of the company’s stock worth $65,000 after buying an additional 215,200 shares during the last quarter. Institutional investors and hedge funds own 9.21% of the company’s stock.

About Iterum Therapeutics

(Get Free Report)

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.

Read More

Receive News & Ratings for Iterum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iterum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.